Toshiaki Takahashi Selected Research

Miyoshi myopathy

4/2013	Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B.
1/2012	[A case of dysferlinopathy asymptomatic for 10 years after an episode of transient muscle weakness].
1/2010	Rapid screening for Japanese dysferlinopathy by fluorescent primer extension.
11/2005	[Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)].
10/2004	[A patient with distal muscular dystrophy without mutations in dysferlin gene but with abnormal dysferlin localization in muscle fibers].
5/2004	Novel dysferlin mutations and characteristic muscle atrophy in late-onset Miyoshi myopathy.
12/2002	Miyoshi myopathy patients with novel 5' splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshiaki Takahashi Research Topics

Disease

143	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022 - 02/2007
107	Neoplasms (Cancer) 09/2022 - 05/2003
31	Lung Neoplasms (Lung Cancer) 09/2022 - 09/2004
28	Congenital Diaphragmatic Hernias 02/2021 - 08/2014
24	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 08/2007
21	Neoplasm Metastasis (Metastasis) 12/2021 - 01/2010
17	Disease Progression 01/2021 - 12/2002
14	Hypoxia (Hypoxemia) 01/2017 - 08/2010
12	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021 - 08/2009
12	Adenocarcinoma 12/2020 - 02/2007
12	Adenocarcinoma of Lung 02/2018 - 01/2011
11	Neutropenia 12/2020 - 03/2014
7	Febrile Neutropenia 12/2020 - 01/2016
7	Dysferlinopathy 01/2020 - 05/2005
7	Wounds and Injuries (Trauma) 01/2020 - 12/2006
7	Thymoma (Thymic Carcinoma) 01/2017 - 12/2009
7	Miyoshi myopathy 04/2013 - 12/2002
6	Pneumonia (Pneumonitis) 04/2022 - 08/2016
6	Diarrhea 01/2022 - 08/2009
6	Anorexia 07/2021 - 08/2009
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018 - 12/2009
6	Osteosarcoma (Osteogenic Sarcoma) 09/2004 - 10/2003
5	Cachexia 01/2022 - 11/2017
5	Malignant Mesothelioma 09/2019 - 03/2010
5	Carcinoma (Carcinomatosis) 05/2017 - 04/2010
5	Thrombocytopenia (Thrombopenia) 01/2017 - 11/2009
4	Inflammation (Inflammations) 01/2022 - 09/2018
4	Muscular Dystrophies (Muscular Dystrophy) 01/2022 - 11/2004
4	Breast Neoplasms (Breast Cancer) 09/2018 - 03/2011
4	Vascular Remodeling 02/2018 - 05/2015
4	Nausea 09/2017 - 11/2010
4	Pain (Aches) 07/2017 - 10/2004
4	Pulmonary Hypertension 02/2017 - 01/2011
4	Muscular Diseases (Myopathy) 12/2015 - 12/2005
3	Infections 03/2021 - 05/2014
3	Melanoma (Melanoma, Malignant) 01/2020 - 03/2016
3	Appendicitis 12/2019 - 09/2018

Drug/Important Bio-Agent (IBA)

55	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2008
31	Tyrosine Kinase InhibitorsIBA 12/2021 - 11/2008
28	PlatinumIBA 01/2022 - 08/2007
26	nitrofenIBA 02/2021 - 08/2014
25	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2009
21	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2014 - 11/2009
20	Gefitinib (Iressa)FDA Link 01/2022 - 02/2007
18	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2011
15	DysferlinIBA 01/2020 - 12/2002
13	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 02/2007
13	osimertinibIBA 11/2021 - 01/2017
12	Docetaxel (Taxotere)FDA Link 09/2019 - 02/2007
11	B7-H1 AntigenIBA 02/2022 - 12/2018
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 02/2007
11	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 02/2014 - 08/2010
10	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2016
10	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022 - 03/2009
10	NivolumabIBA 01/2021 - 01/2016
10	Glucose (Dextrose)FDA LinkGeneric 02/2014 - 08/2010
9	pembrolizumabIBA 01/2022 - 03/2019
8	Pemetrexed (MTA)FDA Link 01/2022 - 03/2010
8	Etoposide (VP 16)FDA LinkGeneric 12/2020 - 06/2010
8	HexokinaseIBA 02/2014 - 01/2011
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 09/2004
7	Biological ProductsIBA 01/2019 - 08/2010
7	Deoxyglucose (2 Deoxy D glucose)IBA 02/2014 - 08/2010
6	durvalumabIBA 04/2022 - 10/2020
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 02/2007
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 04/2009
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2014 - 05/2011
5	Pharmaceutical PreparationsIBA 01/2022 - 04/2010
5	amrubicinIBA 11/2019 - 08/2007
5	Thymidylate SynthaseIBA 01/2014 - 09/2011
5	TOR Serine-Threonine KinasesIBA 10/2013 - 01/2011
4	ParaffinIBA 01/2021 - 04/2014
4	Formaldehyde (Formol)FDA Link 01/2021 - 04/2014
4	Anaplastic Lymphoma KinaseIBA 10/2020 - 07/2015
4	Gemcitabine FDA Link 06/2019 - 10/2009
4	CrizotinibIBA 10/2018 - 09/2013
4	Bevacizumab (Avastin)FDA Link 11/2016 - 06/2013
4	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2014 - 09/2011
4	Orotate PhosphoribosyltransferaseIBA 01/2014 - 09/2011
4	Free RadicalsIBA 09/2004 - 10/2003
4	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 09/2004 - 10/2003
4	Hydroxyl RadicalIBA 09/2004 - 10/2003
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 12/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2013
3	130-nm albumin-bound paclitaxelIBA 01/2022 - 03/2019
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 05/2004
3	Therapeutic UsesIBA 01/2022 - 11/2011
3	antigen CYFRA21.1IBA 01/2020 - 07/2013

Therapy/Procedure

75	Drug Therapy (Chemotherapy) 02/2022 - 02/2007
62	Therapeutics 09/2022 - 05/2005
29	Radiotherapy 01/2022 - 05/2003
20	Chemoradiotherapy 01/2022 - 12/2009
10	Adjuvant Chemotherapy 12/2020 - 03/2009
9	Aftercare (After-Treatment) 11/2021 - 05/2011
6	Catheters 01/2019 - 12/2015
4	Activities of Daily Living (ADL) 07/2021 - 03/2005
4	Appendectomy 12/2019 - 09/2010
4	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 01/2013
4	Cranial Irradiation 04/2018 - 01/2017
3	Immunotherapy 01/2022 - 01/2021